Program of Formative Meetings in Pulmonary Hypertension in the Marqués de Valdecilla University Hospital

26 de September de 2019

Background and objective

The Pulmonary Hypertension Unit of the Marqués de Valdecilla University Hospital of Santander is one of the most experienced units in Spain, along with the Hospital October 12, Madrid and the Hospital Clinic of Barcelona and concentrates an important clinical and research activity in this field.

The Pulmonary Hypertension Unit is led by the Pulmonology Service, a reference National lung transplant. Multiple services participate in the HAP Unit those that highlight the Cardiology Service with the Imaging Unit (echocardiography, Magnetic Resonance) and the Hemodynamics Unit, the Rheumatology Service with extensive experience in systemic diseases, the Pharmacy Service, the Service of Radiology, the Digestive Service, the Pharmacy Service and the medical-surgical team of the Pulmonary Transplant program, among others.

This Unit develops an intense teaching activity in Pulmonary Hypertension, having completed at least 10 editions of theoretical and practical courses of Hypertension Pulmonary focal raised in national professionals dedicated to PAH.

The objective of the program is to expand knowledge and skills in hypertension pulmonary for which it is proposed to hold a monthly meeting on the second Thursday of each month from 4:00 p.m. to 6:30 p.m.

Formative Meetings

Theoretical and clinical training will take place every month that will cover the following topics:

  • Definition, classification and epidemiology of pulmonary hypertension.
  • Function and adaptation of the right ventricle in pulmonary hypertension.
  • Genetics of pulmonary arterial hypertension.
  • Diagnostic algorithm and prognostic assessment in pulmonary hypertension
  • Non-invasive imaging techniques in pulmonary hypertension: echocardiography, resonance Cardiac and CT.
  • Right heart catheterization and pulmonary arteriography.
  • General measures and conventional treatment. Pregnancy and contraception. Rehabilitation.
  • Nitric oxide pathway and PDE-5 inhibitors. Antagonists of the receptors of the endothelin Stimulators of guanylate cyclase.
  • Prostacycline analogs and prostacycline IP receptor agonists.
  • Treatment for objectives in pulmonary hypertension
  • Pulmonary / cardiopulmonary transplant and atrial septostomy
  • Idiopathic pulmonary arterial hypertension.
  • Pulmonary hypertension associated with toxic rapeseed oil.
  • Pulmonary Venoocclusive Disease
  • Pulmonary hypertension associated with connective tissue diseases
  • Pulmonary hypertension associated with HIV and portopulmonary.
  • Pulmonary hypertension associated with congenital heart disease in adults.
  • Pulmonary hypertension in pediatrics.
  • Follow-up of the patient with pulmonary thromboembolism. Hypertension Treatment chronic thromboembolic lung.
  • Pulmonary hypertension in chronic respiratory pathology
  • Pulmonary hypertension in left heart disease.

Calendar of Formative Meetings (OCTOBER 19-DECEMBER-19)

  • Venue: training room nº7, pavilion 16, 2nd floor. HUMV
  • Hours: 16:00-18:30h

OCTOBER 10, 2019: Risk measurement in pulmonary hypertension (echocardiography, ergometry)

NOVEMBER 14, 2019: Clinical trials in Pulmonary Hypertension.

DECEMBER 12, 2019: Bibliographic session of Pulmonary Hypertension.